Evaluate for Investment Banking
Build stronger pharma and biotech deal strategies with trusted market intelligence
Why Evaluate
Why investment banking teams use Evaluate
In pharma and biotech investment banking, strong client advice depends on understanding the market evidence behind the deal.
Banking teams need to assess where value sits, how durable the opportunity is, which assets or companies are strategically attractive, and what clinical, regulatory or competitive events could affect timing, valuation or market perception.
Evaluate brings together company, drug, forecast, pipeline and catalyst intelligence so teams can build stronger pitch materials, challenge assumptions, support valuation work and give clients more confident recommendations.
companies covered
pharma and biotech products tracked
consensus forecasts
products back to 2003
Featured insight
Global prescription drug sales are forecast to exceed $2 trillion by 2032, driven by a new era of obesity and autoimmune blockbusters, sustained M&A activity, and a dealmaking landscape that is shifting quickly. Growth remains strong and the R&D pipeline is healthy. But pricing pressure, regulatory uncertainty, and China’s emergence as the dominant source of licensed pipeline assets are raising urgent questions about where value will be created next.
Evaluate’s annual World Preview puts the data behind the decisions.
Trusted intelligence across the pharma and biotech ecosystem
- Forecasts to 2032 for forward-looking market sizing and investment evaluation
- Historic sales data back to 1996 for long-term performance context
- Coverage across private and listed biopharma companies, marketed products and pipeline assets
Built for key investment banking workflows
Get in touch
M&A target screening and market mapping
- Build target lists around therapy areas, geographies or market segments
- Compare companies by portfolio, pipeline strength or forecast potential
- Support buy-side, sell-side or strategic advisory work
Client pitch and meeting preparation
- Build sharper pitch materials
- Identify timely client conversation starters
- Support recommendations with market and product-level evidence
IPO and capital raising support
- Support IPO or financing preparation
- Size the commercial opportunity
- Strengthen the growth story behind a raise
Asset valuation and scenario planning
- Pressure-test valuation assumptions
- Build or validate NPV models
- Compare upside and downside cases
Catalyst and deal timing analysis
- Monitor live deal risks
- Prepare for market-moving events
- Understand what could shift valuation or timing
Licensing and partnership advisory
- Evaluate licensing or co-development opportunities
- Compare assets within a therapy area
- Advise clients on strategic options
Comparable company and peer benchmarking
- Support valuation and benchmarking work
- Strengthen client materials with peer context
- Assess how a company or asset compares in the market
The data and tools behind the workflows
Consensus forecasts and sales data
Company and asset coverage
Pipeline intelligence
NPV Analyzer
Calendar of Events
Peer Group Analyzer
Report Builder
Venture financing and deal intelligence
News & Insights
Keep up to date with the market signals shaping pharma and biotech investment decisions through expert analysis, exclusive interviews and market commentary from Scrip, In Vivo, Pink Sheet and Medtech Insight, covering key deals, strategy shifts, leadership changes, regulatory developments and wider biopharma market trends.
Bring more evidence to every investment decision
Learn how Evaluate can help your team assess opportunities, understand market potential and make more confident decisions across pharma and biotech.
Choose a time to talk
Book directly with one of our specialists. No forms. No waiting. A focused conversation with someone who knows the data.
Typically 30 minutes, with a specialist matched to your sector
No obligation. Cancel or reschedule any time
Share a few details and we'll be in touch
We’ll help you understand how Evaluate can support your investment workflows, research priorities and decision-making.
Frequently Asked Questions
How can Evaluate support M&A target screening?
Evaluate helps banking teams identify and assess pharma and biotech companies by product portfolio, pipeline strength, forecast potential, therapy area focus, market exposure and competitive position.
This supports target list creation, market mapping and early prioritization for buy-side, sell-side or strategic advisory work.
How does Evaluate support client pitch preparation?
Evaluate provides company, asset, forecast, pipeline, peer and catalyst intelligence that can be used to strengthen pitch materials and client conversations.
This helps teams bring more relevant market context, sharper deal angles and better evidence into meetings.
Can Evaluate support IPO and capital raising work?
Yes. Evaluate helps teams assess market size, product potential, competitive positioning, clinical milestones, peer companies and long-term revenue opportunity.
This can support IPO preparation, investor materials, financing narratives and growth story development.
How can Evaluate help with valuation and scenario planning?
Evaluate’s forecast data and NPV tools help teams test assumptions around future sales, pricing, launch timing, competitive threats, biosimilar risk, costs and development scenarios.
This can support NPV modelling, upside and downside cases, and more defensible client recommendations.
Can Evaluate help with licensing and partnership advisory?
Yes. Evaluate helps teams assess asset attractiveness, comparable products, forecast opportunity, competitor dynamics and potential strategic fit.
This supports licensing, co-development, partnership and broader strategic advisory conversations.
How does Evaluate help teams track deal timing and risk?
Evaluate tracks clinical, regulatory, legal and commercial catalysts including trial readouts, approvals, PDUFA dates, patent events, litigation, product launches and M&A activity.
This helps teams monitor live deal risks, identify timely client conversation starters and understand what could affect valuation or transaction timing.
